Compare ASIC & MNKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ASIC | MNKD |
|---|---|---|
| Founded | 2018 | 1991 |
| Country | United States | United States |
| Employees | 203 | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.2B |
| IPO Year | 2025 | 2004 |
| Metric | ASIC | MNKD |
|---|---|---|
| Price | $26.39 | $3.94 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 8 |
| Target Price | ★ $29.10 | $7.97 |
| AVG Volume (30 Days) | 51.7K | ★ 3.7M |
| Earning Date | 10-21-2026 | 11-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 23.44 | N/A |
| EPS | ★ 1.18 | N/A |
| Revenue | ★ $424,339,000.00 | $348,966,000.00 |
| Revenue This Year | $27.91 | $27.07 |
| Revenue Next Year | $25.28 | $13.65 |
| P/E Ratio | $22.21 | ★ N/A |
| Revenue Growth | ★ 23.41 | 22.23 |
| 52 Week Low | $16.35 | $2.23 |
| 52 Week High | $29.00 | $6.51 |
| Indicator | ASIC | MNKD |
|---|---|---|
| Relative Strength Index (RSI) | 44.42 | 63.67 |
| Support Level | $18.75 | $3.77 |
| Resistance Level | $27.22 | $4.29 |
| Average True Range (ATR) | 0.80 | 0.21 |
| MACD | -0.30 | 0.05 |
| Stochastic Oscillator | 11.16 | 90.05 |
Ategrity Specialty Insurance Co Holdings is a specialty property and casualty insurance holding company focused on the excess and surplus market for small to medium-sized businesses (SMBs) across the United States. Operating through its subsidiaries, the company underwrites small and medium-sized commercial risks across selected industry verticals, including Retail, Real Estate, Hospitality, and Construction. Its operating model uses a technology-driven method to standardize, simplify, and, where appropriate, automate these transactions. The group distributes its products through licensed surplus lines brokers and wholesale agents.
MannKind Corp is a biopharmaceutical company focused on the development and commercialization of patient-centric therapies that address serious unmet medical needs for those living with cardiometabolic and orphan lung diseases. The Company is currently commercializing three products: Afrezza (insulin human) Inhalation Powder, an ultra rapid-acting inhaled insulin indicated to improve glycemic control in adults with diabetes; Furoscix (furosemide injection), to treat fluid buildup in patients with chronic heart failure or chronic kidney disease; and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults that require insulin.